| |
|
|
|
Xtalks, Online
2024-09-05
This informative webinar will provide a comprehensive examination of the development lifecycle of radionuclide conjugates and antibody-drug conjugates from initial research to clinical application.
With innovation, investment, and regulatory support accelerating radionuclide conjugate and antibody-drug conjugate research, understanding the drug development landscape is crucial to recognizing opportunities for development, anticipating challenges, and strategizing effectively. Knowledge of regulatory constructs and efficient clinical development — including study design, dose and regimen selection and optimization — is essential to navigate the complex approval process and maximize therapeutic efficacy while minimizing side effects.
Read more...
Register for this webinar today to gain a deeper understanding of the transformative potential of antibody-drug conjugates and radionuclide conjugates and learn why they are pivotal in the advancement of precision medicine and significantly improving patient outcomes in oncology.
Keywords: Drug Development, Precision Medicine, Clinical Research, CRO, Oncology, Therapeutic Areas, Antibody Drug Conjugates, PK, Data Science, Oncology Drug Development, Precision Oncology
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Alex MacDonald, PhD, Vice President, Model-Informed Drug Development, Allucent
Sugato De, MS, Vice President, Regulatory Strategy, Head of Medical Technology, Allucent
Angela Brady, MHL, Senior Vice President, Global Head of Project Leadership and Client Relations, Allucent
Dr. Brian Barnett, MD, Executive Medical Director, Oncology, Allucent
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-09-05
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|